OR52I2: A Potential Drug Target and Biomarker for Ovarian Cancer

OR52I2: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, affecting an estimated 21,000 new cases and 12,000 deaths in the United States alone each year. Despite advances in surgical and radiation treatments, the survival rate for ovarian cancer remains largely the same, highlighting the need for new treatments with high potency. The olfactory receptor OR11-12 has been identified as a potential drug target and biomarker for ovarian cancer, providing new avenues for cancer research and development.

The olfactory receptor OR11-12 is a transmembrane protein that plays a crucial role in the sense of smell. OR11-12 is expressed in various tissues, including the brain, and is involved in the transduction of sensory information from the nose and mouth to the brain. OR11-12 has also been shown to be involved in the regulation of stem cell proliferation and the development of cancer.

Recent studies have suggested that OR11-12 may be a drug target for ovarian cancer due to its unique expression and involvement in cancer progression. OR52I2, a potential drug candidate, has been shown to interact with OR11-12 in various cellular and tissue samples from ovarian cancer patients. Additionally, OR52I2 has been shown to inhibit the growth and migration of ovarian cancer cells in cell culture and animal models, leading to a reduction in the population of ovarian cancer cells.

The potential implications of targeting OR11-12 with drugs could be significant. By inhibiting the function of OR11-12, researchers could potentially reduce the growth of ovarian cancer cells and slow down the progression of the disease. This could lead to improved survival rates and a reduced risk of recurrence.

In addition to its potential as a drug target, OR52I2 has also been identified as a potential biomarker for ovarian cancer. The ability to detect and measure the expression of OR11-12 in cancer cells and tissues could be used as a diagnostic tool for ovarian cancer, as well as a target for personalized medicine. By identifying individuals who have high levels of OR11-12 expression, doctors could potentially identify those at risk for ovarian cancer and direct them to early detection and treatment.

OR52I2 has also been shown to be involved in the regulation of stem cell proliferation, which could have implications for the development of cancer. By inhibiting the activity of OR11-12, researchers could potentially reduce the number of stem cells that differentiate into cancer cells. This could lead to a reduction in the overall number of cancer cells and improve the effectiveness of cancer treatments.

In conclusion, OR52I2 is a promising drug target and biomarker for ovarian cancer. Its unique expression and involvement in cancer progression make it an attractive candidate for drug development. Further research is needed to fully understand the potential implications of targeting OR11-12 with drugs and to determine its effectiveness as a biomarker for ovarian cancer. However, the potential of OR52I2 as a drug target and biomarker for ovarian cancer is clear, and further studies are needed to uncover its full potential.

Protein Name: Olfactory Receptor Family 52 Subfamily I Member 2

Functions: Odorant receptor

The "OR52I2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR52I2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR52J3 | OR52K1 | OR52K2 | OR52K3P | OR52L1 | OR52M1 | OR52N1 | OR52N4 | OR52N5 | OR52R1 | OR52W1 | OR52Z1P | OR56A1 | OR56A3 | OR56A4 | OR56A5 | OR56B1 | OR56B4 | OR5A1 | OR5A2 | OR5AC1 | OR5AC2 | OR5AK2 | OR5AK4P | OR5AN1 | OR5AP2 | OR5AR1 | OR5AS1 | OR5AU1 | OR5B12 | OR5B17 | OR5B2 | OR5B21 | OR5B3 | OR5BA1P | OR5C1 | OR5D13 | OR5D14 | OR5D16 | OR5D17P | OR5D18 | OR5E1P | OR5F1 | OR5H1 | OR5H14 | OR5H15 | OR5H2 | OR5H4P | OR5H6 | OR5I1 | OR5K1 | OR5K2 | OR5K3 | OR5K4 | OR5L1 | OR5L2 | OR5M1 | OR5M10 | OR5M11 | OR5M3 | OR5M4P | OR5M8 | OR5M9 | OR5P1P | OR5P2 | OR5P3 | OR5T1 | OR5T2 | OR5T3 | OR5V1 | OR5W2 | OR6A2 | OR6B1 | OR6B2 | OR6B3 | OR6C1 | OR6C2 | OR6C3 | OR6C4 | OR6C65 | OR6C70 | OR6C74 | OR6C75 | OR6C76 | OR6F1 | OR6J1 | OR6K2 | OR6K3 | OR6M1 | OR6N1 | OR6N2 | OR6P1 | OR6Q1 | OR6R2P | OR6S1 | OR6T1 | OR6W1P | OR6X1 | OR6Y1 | OR7A10